The present disclosure relates to cardiac ablation systems, and more particularly to a cardiac ablation system and process providing image analysis for determining the quality of lesions formed during a surgical ablation procedure.
Cardiac arrhythmias (e.g., fibrillation) are irregularities in the normal beating pattern of the heart and can manifest themselves in either the atria or the ventricles of the heart. For example, atrial fibrillation is a form of arrhythmia characterized by rapid randomized contractions of atrial myocardium, causing an irregular, often rapid ventricular rate. The regular pumping function of the atria is replaced by a disorganized, ineffective quivering as a result of chaotic conduction of electrical signals through the upper chambers of the heart. Atrial fibrillation is often associated with other forms of cardiovascular disease, including congestive heart failure, rheumatic heart disease, coronary artery disease, left ventricular hypertrophy, cardiomyopathy, or hypertension.
It is now understood that recurrent atrial fibrillation (paroxysmal and persistent) is triggered by rapidly firing tissue, (called “ectopic foci”), that are located in one or more of the four pulmonary veins, which attach to the rear of the left atrium. It has been found that atrial fibrillation may be cured by electrically isolating the pulmonary veins from the rest of the atrium.
Various techniques have been employed for pulmonary vein isolation. A common purpose of each of these techniques is to replace cardiac muscle cells with scar tissue, which scar tissue cannot conduct normal electrical activity within the heart.
In one known approach, circumferential ablation of tissue within the pulmonary veins has been practiced to treat atrial fibrillation. By ablating the heart tissue at selected locations, electrical conductivity from one segment to another can be blocked and the resulting segments become too small to sustain the fibrillatory process on their own.
Several types of ablation devices have recently been proposed for creating lesions to treat cardiac arrhythmias. Many of the recently proposed ablation instruments are percutaneous devices that are designed to create such lesions from within the heart. Such devices are positioned in the heart by catheterization of the patient, e.g., by passing the ablation instrument into the heart via a blood vessel, such as the femoral vein.
Typically, percutaneous devices are positioned with the assistance of a guide wire, which is first advanced into heart. In one common approach, a guide wire or similar guide device is advanced through the left atrium of the heart and into a pulmonary vein. A catheter instrument with an expandable element is then advanced over the guide wire and into the pulmonary vein where the expandable element (e.g., a balloon) is inflated. The balloon includes a circumferential ablation element, e.g., an energy emitting device, such as a laser, disposed in the inner surface of the balloon, which performs the ablation procedure.
It is noted that ablation within the pulmonary vein can result in complications. Overtreatment deep within a vein can result in stenosis (closure of the vein itself), necrosis or other structural damage, any of which can necessitate immediate open chest surgery. Conversely, undertreatment in which scar tissue formed is not continuous and/or insufficient to replace the cardiac muscles sought to be electrically isolated from the atrium will cause the surgical ablation procedure to be unsuccessful. Thus, repeating of the surgical ablation procedure is then required which is almost always undesirable. The term “continuous” in the context of a lesion is intended to mean a lesion that substantially blocks electrical conduction between tissue segments on opposite sides of the lesion.
In accordance with a broad aspect of the invention, the present invention provides for a cardiac ablation system that allows for a user or operator to generate a record of the locations within a surgical site, wherein sufficient ablative energy has been directed. The tissue ablation system is electronically coupled to a tissue ablation instrument which forms lesions on tissue. The tissue ablation system includes a processing system for determining the sufficiency of lesions formed on tissue at a surgical site by evaluating operating data received from the tissue ablation instrument.
In more particular aspects, the present invention provides a system that records still and continuous video images from a surgical site with an image recording device. A colored aiming light, in conjunction with a white illuminating light, is used to direct ablative energy to tissue in need of treatment. The image recording device is used to transmit the image of the surgical site to an operator in real-time. Upon activation of the ablation laser, ablative energy is delivered to tissue. Immediately prior to delivery of the ablative energy, the image recording device records a still image from the live video feed. The still image is then depicted on a display next to the continuing live video feed of the surgical site. Due to the reflection of the aiming light, it is possible to identify where the energy was delivered (and where ablation has occurred). Therefore, the system allows a user to aim the ablative energy emission at another area of the surgical site that needs treatment (e.g., a gap in lesion), without the danger of over treating an area of the surgical site. Furthermore, each time ablative energy is delivered, another still image is taken during the activation and that image is overlaid on the previous still image. The transparency of each image can be modified so that the aiming marker native to each image will be visible through the image layers. In this way, a user can construct a time or emission based map of the treated areas in a surgical site.
The advantages of this system are apparent. The cardiac ablation system envisioned uses live and still imagery to view a surgical site. By providing an aiming light, the user is able to determine where the ablative energy will be deposited. Furthermore, by recording an image of the surgical site at the time of depositing, the user has a record of which areas have been treated. Additionally, by overlaying a series of images taken during discrete ablative treatments, a user can construct a track or trace of the path of the energy at the surgical site. This allows the user to view the surgical site without obstruction, with the confidence that no excessive or damaging energy will be deposited to locations where it is not needed or already treated. The system further enables a user to create a time-lapse map of the path taken or the order of lesions treated.
These and other aspects, features and benefits of the invention can be further appreciated from the accompanying drawings, which illustrate certain embodiments of the invention together with the detailed description thereof.
The objects and features of the invention may be understood with reference to the following detailed description of an illustrative embodiment of the present invention taken together in conjunction with the accompanying drawings in which:
The present invention will now be described more fully with reference to the accompanying drawings, in which illustrated embodiments of the present invention are shown. The present invention is not limited in any way to any of the illustrated embodiments.
As will also be appreciated from the below discussion, an endoscope is preferably provided in ablation instrument 100 and has the capability of capturing both live images and recording still images. An illumination light is used to provide operating light to the surgical site. The illumination light is of a frequency that allows the user to differentiate between different tissues present at the operating site. An aiming light source 20 is used to visualize the location where energy will be delivered by the ablation instrument 100 to tissue. It is envisioned that the aiming light will be of a wavelength that can be recorded by an image capture device and visible on a display.
The processor 12 is designed to process live visual data as well as data from the ablation instrument controllers and display. The processor is configured execute a series of software and/or hardware modules configured to interpret, manipulate and record visual information received from the surgical site. The processor 12 is further configured to manipulate and provide illustrative and graphical overlays and composite or hybrid visual data to the display device. The image processor 12 has code executing on a processor that is operative to configure the image processor to generate an image of a lesion formed by ablation instrument 10 and determine the quality of the lesion based on operating information received from the ablation instrument 100.
As seen in
The aiming light source 20 is used to visualize the surgical site location 120 where energy will be delivered by the ablation instrument 100 to tissue 130. Preferably, the aiming light source 20 outputs light in a visible region of the electromagnetic spectrum. If a suitable ablation path is seen by the user, the controller 16 transmits radiant energy, via energy source 18, from the ablation instrument 100 to a target tissue site 120 to effect ablation by lesions. It is to be appreciated that the term “radiant energy” as used herein is intended to encompass energy sources that do not rely primarily on conductive or convective heat transfer. Such sources include, but are not limited to, acoustic, laser and electromagnetic radiation sources and, more specifically, include microwave, x-ray, gamma-ray, ultrasonic and radiant light sources. Additionally, the term “light” as used herein is intended to encompass electromagnetic radiation including, but not limited to, visible light, infrared and ultraviolet radiation.
The illumination light source is a light source used to provide proper illumination to the surgical site. The illuminate is configured so that natural biological tones and hues can be easily identifiable by an operator.
The controller 16 can provide the user with the ability to control the function of the aiming light source, the user input devices, and the ablation instrument. The controller serves as the primary control interface for the ablation system. Through the controller, the user can turn on and off both the aiming and illumination lights. Furthermore the controller possesses the ability to change the illumination and aiming light intensity. The ability to switch user interfaces or display devices is also envisioned. Additionally, the controller gives access to the ablation instrument, including control over the intensity of the discharge, duration and location of ablative energy discharges. The controller 16 can further provide a safety shutoff to the system in the event that a clear transmission pathway between the radiant energy source and the target tissue is lost during energy delivery (e.g., see commonly owned U.S. patent application Ser. No. 12/896,010, filed Oct. 1, 2010, which is hereby incorporated by reference in its entirety.
The controller can be a separate microprocessor based control interface hardware or it can be a portion of a configured as a module operating through a processor based computer system configured to accept and control inputs from various physical devices.
As shown in
With further reference to
The multiple view module 220 includes instructions for configuring the processor 12 to provide multiple images to the display. The multiple view module configures the display to depict at least two image depiction areas. In a first image depiction area, the live video stream of the surgical site is displayed to the user. In a second image depiction area, a still image, highlighting the last target of ablative energy is depicted.
The composite module 222 includes instructions for combining a series of still images and producing a composite image that depicts the target location of the ablative emission in each still image. The compositing module 222 can be implemented as discrete sub-modules to provide functions such as altering the transparency of each still image layer of the composite image so that a time based map of ablation locations can be produced. Another function implemented by the submodules is construction of a video or slideshow from a sequence of still images.
The mapping module 224 includes instructions for overlaying proposed treatment paths on the live image. The mapping module is configured to show colored markers indicating acceptable levels of ablative energy depositing. For example the mapping module is capable of generating a green colored visual marker and superposing it over the live image to indicate areas that have yet to receive levels of ablative energy necessary for treatment. Conversely, the mapping module 224 is also capable of simultaneously generating a red colored (or other color) visual marker and superimposing it over the live image to indicate areas that have received sufficient quantities of ablative energy suitable lesions. The mapping module 224 can be implemented as discrete sub-modules to provide functions such as receiving data on the duration and intensity of an ablative emission and correlating that specific instance to a specific stored image.
The illustrating module 226 includes instructions for providing a image to the display, wherein the image is an illustration or graphical representation of the surgical site. The illustrating module 226 is configured to allow annotation of the illustrated image as well as comparison between the live image and the illustrated image. For example, and as shown in
The control module 220 includes instructions for orientating and accessing the functions of each of the other modules, as well as communicating with the controller and inputting information or manipulating the parameters of the data being displayed during operation. The manipulation and controlling functions can be implemented as discrete sub-modules with instructions for selecting operation modes, control interfaces, display orientation, recording modes, storage device location and data entry.
The user refers to the live video feed from the image capture device to determine where to direct a radiant energy transmission. Upon first use of the device, a live video image and a still image of the surgical site are depicted on the display. As seen in
The live video shown to the user will allow the user to see the reflection of the aiming light 218 and hence direct ablative energy. It is envisioned that the first still image 210 depicted will be a still image captured at a point in time prior to the initiation of the first radiant energy emission. For instance, at a point in time prior to the emission of radiant energy, the image capture device records an image 210 of the surgical site 152 that depicts the surgical site 152 without the aiming light. By taking a still image 210 of the site, the user can record a baseline image of the surgical site before any treatment has been commenced. Furthermore, through the functions of the illustrative module, an illustration of the untouched 152 can be generated. During emission of radiant energy a still image 210 is taken of the surgical site 152. The characteristics of the ablative event (e.g. information regarding the duration and intensity of the radiant of the energy emission) are stored and associated with the image depicting that specific emission. In addition, the reflection of the aiming light will be visible in the still image, providing a location indicator as to where the energy was directed. A series of these still images can be combined by using the composite module. By modifying the opacity of each image, the reflected light of the aiming light for each ablative event will be visible in the composite image. In this way, a complete record 220 of where energy was directed will becomes available. Furthermore, because the composite image is composed a series of individual images representing a specific period of time during the procedure, a time based map of the entire operation can also be produced in real time or for subsequent review.
Also visible in
It is to be appreciated the invention is not to be understood to be limited to the two image depiction areas discussed above with reference to
Therefore, if the user is not satisfied with the quality of the lesion produced, or the modules indicate that a sufficient lesion was not produced, the user can promptly redo the treatment of a specific tissue location (spot treatment). Conversely, if the modules indicate that a sufficient lesion was formed, the user can confidently move on to a new tissue location to continue the treatment thus saving time and effort by avoiding the need to more closely examine the tissue location that was just treated. Hence, once the entire treatment is performed, the modules of the system permit the surgeon to view all treatment segments forming the entire ablation arc to see if a continuous, uninterrupted ablation has been formed (or see if the ablation has the intended, desired shape). If there are visible gaps or other imperfections with the formed ablation, the surgeon can move the energy transmitter 140 to the proper location for retreatment of these areas until the desired ablation is formed. The process can then be repeated to determine and confirm that the gap was eliminated.
As a result, the mapping, analyzing and illustrating functions performed by the ablation system of the present invention overcome the disadvantages associated with prior ablation surgical procedures and results in increased ablation success rates due to a more optimal and more accurate viewing and quality determination of the spot lesions created to form the continuous ablation at the tissue location for the surgical site 152.
With reference now to
It should be understood that the embodiments illustrated in the drawings are only a few of the cardiac ablation instruments that can be utilized in accordance with the present invention. Further descriptions of other embodiments can be found, for example, in commonly owned, co-pending U.S. patent application Ser. No. 10/357,156, filed Feb. 3, 2003, U.S. patent application Ser. No. 09/924,393, filed Aug. 7, 2001 and which is expressly incorporated by reference.
With reference now to
The radiant energy emitter 40 is shown in
Also disposed within the instrument 100 is a reflectance sensor, preferably an endoscope 176 capable of capturing an image of the target site 152 and/or the instrument position. The endoscope 176 is typically an optical fiber bundle with a lens or other optical coupler at its distal end to receive light. The reflectance sensor/endoscope can also include an illumination source, such one or more optical fibers coupled to a light source or sources. Endoscopes are available commercially from various sources. The endoscope can further include an optical head assembly, as detailed in more detail below, to increase the field of view. In one illustrated embodiment, ablation element 140 and endoscope 176 are adapted for independent axial movement within the catheter body 14.
The term “endoscope” as used herein is intended to encompass optical imaging devices, generally, including but not limited to endoscopes, fiberscopes, cardioscopes, angioscopes and other optical fiber-based imaging devices. More generally, “endoscope” encompasses any light-guiding (or waveguide) structure capable of transmitting an “image” of an object to a location for viewing, such as display 14.
Preferably, spot lesions are formed at the target site 152 by applying radiant energy from the energy transmitter 140 to target tissue. The applied radiant energy may be applied in an energy range from about 50 Joules/cm2 to about 1000 Joules/cm2, or preferably from about 75 Joules/cm2 to about 750 Joules/cm2. The power levels applied by the energy emitter can range from about 10 Watts/cm2 to about 150 Watts/cm2 and the duration of energy delivery can range from about 1 second to about 1 minute, preferably from about 5 seconds to about 45 seconds, or more preferably from about 10 to about 30 seconds. For example, for power levels between 10 and 75 Watts/cm2 it can be advantageous to apply the radiant energy for about 30 seconds. Lesser durations, e.g., of 10 to 20 seconds, can be used for power levels of 75 to 150 Watts/cm2. It is to be understood the above figures are provided as examples and the energy, power and time duration figures set forth above are provided merely as examples and are not to be understood to be limited thereto.
In the illustrated embodiment of the ablation instrument 100 shown in
Since the radiant energy (e.g., a laser) emitted from the energy emitter 140 is typically outside the visual light spectrum that can be detected by the human eye, the ablation instrument 100 includes an aiming light preferably having a pulsed operating mode in which visible light from the aiming light unit is delivered in pulses to cause intermittent illumination of the tissue at the target site 152. This gives the aiming light an appearance of being a blinking light. By delivering the visible aiming light in pulses, the surgeon is able to directly observe the tissue that is being treated at the target site 152, using an endoscope, between the aiming light pulses.
During a surgical ablation procedure, the endoscope 176 is used to determine the extent of tissue ablation by sensing the change in color of the tissue as it is ablated and at a time when the aiming beam is in an off cycle via the display 14. In other words, between the blinking (pulses) of the aiming light, the surgeon can observe the treated tissue to determine how the treatment is progressing since the endoscope 176 is used to determine the extent of tissue ablation by sensing the change in color of the tissue as it is ablated and at a time when the aiming beam is in an off cycle. However, many conditions may cause the actual detection of change in color of tissue being ablated to be difficult and/or unreliable in regards to whether proper spot lesions are formed by the energy transmitter 140 on the tissue at the ablation surgical site 152. For instance, insufficient illumination at the surgical site 152 can make it difficult, if not impossible, to ascertain whether proper spot lesions were formed at the surgical site as viewed on display 14.
The processor 12 of ablator system 10 obviates this problem by determining the quality of the lesion formed on the tissue at the target site 152 which may be viewed on monitor 14 and/or indicated to a surgeon visual overlay or audio cues. With reference now to the flow diagram of
Starting at step 300, the processor 12 captures the image from endoscope 176 of the tissue being ablated at the surgical site. At step 310, the processor 12 also captures information relating to the energy transmitter 140 from controller 16. The captured operating information for the energy transmitter 140 can include, as non-limiting examples: the amount of radiant energy (power) emitted by energy transmitter 140; any reflectance data of energy returning from the tissue at the surgical site 152; the distance the energy transmitter 140 is from tissue to be ablated; the time of application of energy to any one target site; the rate of movement of the energy transmitter 140 from one location to another as ablation continues at the surgical site 152; and the distance between one location at which energy is delivered to the next location of energy delivery. The captured energy transmitter 140 information includes: the amount of radiant energy (power) applied by energy transmitter 140 on the tissue at the surgical site 152 to form spot lesions; the distance the energy transmitter 140 is from tissue to be ablated via spot lesions; and the rate of movement of energy transmitter 140 relative to the tissue at the surgical site 152. It is to be appreciated that aforesaid information captured regarding energy transmitter 140 is not to be understood to be limited thereto as more or less information may be captured that is necessary to determine the quality of the spot lesions formed on the tissue at the surgical site.
The processor 12 then preferably uses algorithmic techniques to determine whether a sufficient spot lesion has just recently been formed on the tissue at the surgical site (step 320). In other words, given the captured operating information such as the distance the energy transmitter 140 is located from the tissue at the surgical site 152, the rate of movement of the energy transmitter 140 relative to the tissue at the surgical site 152 (e.g., the amount of time that energy is applied to the tissue at a given location), and the amount of energy being applied, a determination is made by the image processor 12 as to whether a sufficient spot lesion has been formed on the tissue at a location which the energy transmitter 140 has just applied ablation enemy thereto. As one example, the algorithm can take into account the fact that amount of energy emitted will differ from the amount of energy delivered to tissue due to intervening factors (e.g., travel through an liquid), the distances along which the energy travels from the emitter, estimates of resistances presented by any intervening fluids, and any feedback concerning changes in the albedo of the tissue, as may be determined based on pre-operative captured data or information in a lookup table, can be used by image processor 12, in any combination, as coefficients to gauge the amount of power actually delivered to a particular target location as opposed to the amount of power that was intended to be delivered (which is always greater). In other words, given the distance the energy transmitter 140 is located from the tissue at the surgical site 152, the rate of movement of the energy transmitter 140 relative to the tissue at the surgical site 152 (e.g., the amount of time that energy is applied to the tissue at a given location), and the amount of energy being applied, a determination is made as to whether a sufficient spot lesion has been formed on the tissue at a location which the energy transmitter is applying ablation energy thereto. A lookup table or other similar means may also be used by processor 12 for determining the aforesaid lesion quality. A spot lesion is to be understood as being sufficient when it comprises enough scar tissue effective to block the transmission of electrical signals therethrough.
The processor 12 is preferably further operative and configured to provide a signal to the surgeon indicative of whether a sufficient spot lesion has been formed (step 330). This indicative signal may be provided in the event an insufficient or no spot lesion was formed on the tissue at the surgical site 152 that was subject to the energy transmitter 140 dispersing energy thereto. This indicative signal may be an audio and/or visual signal. The audio signal may consist of a warning tone and the visual signal may consist of a marker (e.g., color red) superimposed on the display 14 illustrating the surgical site 152 (provided via endoscope 176) at the location at which the insufficient spot lesion was determined. Thus, when image processor 12 determines an insufficient spot lesion has been formed, the aforesaid warning signal is promptly provided to the surgeon enabling the surgeon to revisit the tissue having the insufficient lesion and make proper adjustments with the energy transmitter 140 (e.g., apply more energy, close the distance between energy transmitter 140 and the surgical site and/or slow the movement of energy transmitter 140 relative to the surgical site) so as to now form sufficient lesions.
Memory 315 is a memory for storing data and instructions suitable for controlling the operation of processor 310. An implementation of memory 315 would include a random access memory (RAM), a hard drive and a read only memory (ROM). One of the components stored in memory 315 is a program 320.
Program 320 includes instructions for controlling processor 310 to execute method 100. Program 320 may be implemented as a single module or as a plurality of modules that operate in cooperation with one another. Program 320 is contemplated as representing a software embodiment of the method described hereinabove.
User interface 305 includes an input device, such as a keyboard, touch screen, tablet, or speech recognition subsystem, for enabling a user to communicate information and command selections to processor 310. User interface 305 also includes an output device such as a display or a printer. In the case of a touch screen, the input and output functions are provided by the same structure. A cursor control such as a mouse, track-ball, or joy stick, allows the user to manipulate a cursor on the display for communicating additional information and command selections to processor 310.
While program 320 is indicated as already loaded into memory 315, it may be configured on a storage media 325 for subsequent loading into memory 315. Storage media 325 can be any conventional storage media such as a magnetic tape, an optical storage media, a compact disc, or a floppy disc. Alternatively, storage media 325 can be a random access memory, or other type of electronic storage, located on a remote storage system.
The methods described herein have been indicated in connection with flow diagrams that facilitate a description of the principal processes; however, certain blocks can be invoked in an arbitrary order, such as when the events drive the program flow such as in an object-oriented program. Accordingly, the flow diagram is to be understood as an example flow and that the blocks can be invoked in a different order than as illustrated.
It should be understood that various combination, alternatives and modifications of the present invention could be devised by those skilled in the art. The present invention is intended to embrace all such alternatives, modifications and variances that fall within the scope of the appended claims.
Although described in connection with cardiac ablation procedures, it should be clear that the instruments and systems of the present invention can be used for a variety of other procedures where treatment with radiant energy is desirable, including laparoscopic, endoluminal, perivisceral, endoscopic, thoracoscopic, intra-articular and hybrid approaches.
One skilled in the art will appreciate further features and advantages of the invention based on the above-described embodiments. Accordingly, the invention is not to be limited by what has been particularly shown and described, except as indicated by the appended claims. All publications and references cited herein are expressly incorporated herein by reference in their entirety.
The present application claims the benefit of U.S. patent application Ser. No. 61/249,182, filed Oct. 6, 2009, which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3417745 | Sheldon | Dec 1968 | A |
3821510 | Muncheryan | Jun 1974 | A |
4224929 | Furihata et al. | Sep 1980 | A |
4233493 | Nath et al. | Nov 1980 | A |
4273109 | Enderby | Jun 1981 | A |
4336809 | Clark | Jun 1982 | A |
4445892 | Hussein et al. | May 1984 | A |
4585298 | Mori et al. | Apr 1986 | A |
4625724 | Suzuki et al. | Dec 1986 | A |
4660925 | McCaughan, Jr. | Apr 1987 | A |
4701166 | Groshong et al. | Oct 1987 | A |
4718417 | Kittrell et al. | Jan 1988 | A |
4770653 | Shturman | Sep 1988 | A |
4781681 | Sharrow et al. | Nov 1988 | A |
4819632 | Davies et al. | Apr 1989 | A |
4842390 | Sottini et al. | Jun 1989 | A |
4852567 | Sinofsky | Aug 1989 | A |
4860743 | Abela | Aug 1989 | A |
4862886 | Clarke et al. | Sep 1989 | A |
4878492 | Sinofsky et al. | Nov 1989 | A |
4878725 | Hessel et al. | Nov 1989 | A |
4913142 | Kittrell et al. | Apr 1990 | A |
4961738 | Mackin | Oct 1990 | A |
5026367 | Leckrone et al. | Jun 1991 | A |
5030201 | Palestrant | Jul 1991 | A |
5053033 | Clarke | Oct 1991 | A |
5071417 | Sinofsky | Dec 1991 | A |
5078681 | Kawashima et al. | Jan 1992 | A |
5090959 | Samson et al. | Feb 1992 | A |
5098426 | Sklar et al. | Mar 1992 | A |
5109859 | Jenkins | May 1992 | A |
5125925 | Lundahl | Jun 1992 | A |
5133709 | Prince | Jul 1992 | A |
5140987 | Schuger et al. | Aug 1992 | A |
5151096 | Khoury | Sep 1992 | A |
5151097 | Daikuzono et al. | Sep 1992 | A |
5163935 | Black et al. | Nov 1992 | A |
5169395 | Narciso, Jr. | Dec 1992 | A |
5188632 | Goldenberg | Feb 1993 | A |
5188634 | Hussein et al. | Feb 1993 | A |
5190538 | Hussein et al. | Mar 1993 | A |
5196005 | Doiron et al. | Mar 1993 | A |
5207699 | Coe | May 1993 | A |
5209748 | Daikuzono | May 1993 | A |
5219346 | Wagnieres et al. | Jun 1993 | A |
5242438 | Saadatmanesh et al. | Sep 1993 | A |
5261904 | Baker et al. | Nov 1993 | A |
5269777 | Doiron et al. | Dec 1993 | A |
RE34544 | Spears | Feb 1994 | E |
5318024 | Kittrell et al. | Jun 1994 | A |
5330465 | Doiron et al. | Jul 1994 | A |
5337381 | Biswas et al. | Aug 1994 | A |
5350375 | Deckelbaum et al. | Sep 1994 | A |
5363458 | Pan et al. | Nov 1994 | A |
5368564 | Savage | Nov 1994 | A |
5374953 | Sasaki et al. | Dec 1994 | A |
5380316 | Aita et al. | Jan 1995 | A |
5380317 | Everett et al. | Jan 1995 | A |
5395362 | Sacharoff et al. | Mar 1995 | A |
5401270 | Muller et al. | Mar 1995 | A |
5409483 | Campbell et al. | Apr 1995 | A |
5417653 | Sahota et al. | May 1995 | A |
5418649 | Igarashi | May 1995 | A |
5423805 | Brucker et al. | Jun 1995 | A |
5427119 | Swartz et al. | Jun 1995 | A |
5431647 | Purcell, Jr. et al. | Jul 1995 | A |
5437660 | Johnson et al. | Aug 1995 | A |
5441497 | Narciso, Jr. | Aug 1995 | A |
5445608 | Chen et al. | Aug 1995 | A |
5464404 | Abela et al. | Nov 1995 | A |
5482037 | Borghi et al. | Jan 1996 | A |
5496305 | Kittrell et al. | Mar 1996 | A |
5497774 | Swartz et al. | Mar 1996 | A |
5507725 | Savage et al. | Apr 1996 | A |
5531664 | Adachi et al. | Jul 1996 | A |
5536265 | van den Bergh et al. | Jul 1996 | A |
5575766 | Swartz et al. | Nov 1996 | A |
5605162 | Mirzaee et al. | Feb 1997 | A |
5613965 | Muller | Mar 1997 | A |
5643253 | Baxter et al. | Jul 1997 | A |
5649923 | Gregory et al. | Jul 1997 | A |
5653706 | Zavislan et al. | Aug 1997 | A |
5662712 | Pathak et al. | Sep 1997 | A |
5680860 | Imran | Oct 1997 | A |
5690611 | Swartz et al. | Nov 1997 | A |
5693043 | Kittrell et al. | Dec 1997 | A |
5700243 | Narciso, Jr. | Dec 1997 | A |
5702438 | Avitall | Dec 1997 | A |
5722401 | Pietroski et al. | Mar 1998 | A |
5725522 | Sinofsky | Mar 1998 | A |
5759619 | Jin | Jun 1998 | A |
5769843 | Abela et al. | Jun 1998 | A |
5772590 | Webster, Jr. | Jun 1998 | A |
5773835 | Sinofsky | Jun 1998 | A |
5779646 | Koblish et al. | Jul 1998 | A |
5782239 | Webster, Jr. | Jul 1998 | A |
5782899 | Imran | Jul 1998 | A |
5800482 | Pomeranz et al. | Sep 1998 | A |
5807395 | Mulier et al. | Sep 1998 | A |
5823955 | Kuck et al. | Oct 1998 | A |
5824005 | Motamedi et al. | Oct 1998 | A |
5827190 | Palcic et al. | Oct 1998 | A |
5830209 | Savage et al. | Nov 1998 | A |
5833682 | Amplatz et al. | Nov 1998 | A |
5843073 | Sinofsky | Dec 1998 | A |
5845646 | Lemelson | Dec 1998 | A |
5860974 | Abele | Jan 1999 | A |
5885278 | Fleischman | Mar 1999 | A |
5891133 | Murphy-Chutorian | Apr 1999 | A |
5891134 | Goble et al. | Apr 1999 | A |
5904651 | Swanson et al. | May 1999 | A |
5908415 | Sinofsky | Jun 1999 | A |
5931834 | Murphy-Chutorian et al. | Aug 1999 | A |
5938660 | Swartz et al. | Aug 1999 | A |
5947959 | Sinofsky | Sep 1999 | A |
5967984 | Chu et al. | Oct 1999 | A |
5971983 | Lesh | Oct 1999 | A |
5995875 | Blewett et al. | Nov 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6012457 | Lesh | Jan 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6056744 | Edwards | May 2000 | A |
6064902 | Haissaguerre et al. | May 2000 | A |
6071279 | Whayne et al. | Jun 2000 | A |
6071281 | Burnside et al. | Jun 2000 | A |
6071282 | Fleischman | Jun 2000 | A |
6071302 | Sinofsky et al. | Jun 2000 | A |
6086581 | Reynolds et al. | Jul 2000 | A |
6090084 | Hassett et al. | Jul 2000 | A |
6099514 | Sharkey et al. | Aug 2000 | A |
6102905 | Baxter et al. | Aug 2000 | A |
6117071 | Ito et al. | Sep 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6120496 | Whayne et al. | Sep 2000 | A |
6129667 | Dumoulin et al. | Oct 2000 | A |
6146379 | Fleischman et al. | Nov 2000 | A |
6159203 | Sinofsky | Dec 2000 | A |
6161543 | Cox et al. | Dec 2000 | A |
6164283 | Lesh | Dec 2000 | A |
6179835 | Panescu et al. | Jan 2001 | B1 |
6214002 | Fleischman et al. | Apr 2001 | B1 |
6217510 | Ozawa et al. | Apr 2001 | B1 |
6235025 | Swartz et al. | May 2001 | B1 |
6237605 | Vaska et al. | May 2001 | B1 |
6240231 | Ferrera et al. | May 2001 | B1 |
6245064 | Lesh et al. | Jun 2001 | B1 |
6251092 | Qin et al. | Jun 2001 | B1 |
6251109 | Hassett et al. | Jun 2001 | B1 |
6254599 | Lesh et al. | Jul 2001 | B1 |
6270492 | Sinofsky | Aug 2001 | B1 |
6305378 | Lesh | Oct 2001 | B1 |
6312427 | Berube et al. | Nov 2001 | B1 |
6314962 | Vaska et al. | Nov 2001 | B1 |
6325797 | Stewart et al. | Dec 2001 | B1 |
6352531 | O'Connor et al. | Mar 2002 | B1 |
6383151 | Diederich et al. | May 2002 | B1 |
6394949 | Crowley et al. | May 2002 | B1 |
6416511 | Lesh et al. | Jul 2002 | B1 |
6423055 | Farr et al. | Jul 2002 | B1 |
6423058 | Edwards et al. | Jul 2002 | B1 |
6436127 | Anderson et al. | Aug 2002 | B1 |
6471697 | Lesh | Oct 2002 | B1 |
6485485 | Winston et al. | Nov 2002 | B1 |
6500174 | Maguire et al. | Dec 2002 | B1 |
6502576 | Lesh | Jan 2003 | B1 |
6503247 | Swartz et al. | Jan 2003 | B2 |
6514249 | Maguire et al. | Feb 2003 | B1 |
6522933 | Nguyen | Feb 2003 | B2 |
6544262 | Fleischman | Apr 2003 | B2 |
6547780 | Sinofsky | Apr 2003 | B1 |
6554794 | Mueller et al. | Apr 2003 | B1 |
6558375 | Sinofsky et al. | May 2003 | B1 |
6562020 | Constantz et al. | May 2003 | B1 |
6572609 | Farr et al. | Jun 2003 | B1 |
6579278 | Bencini | Jun 2003 | B1 |
6579285 | Sinofsky | Jun 2003 | B2 |
6582536 | Shimada | Jun 2003 | B2 |
6605055 | Sinofsky et al. | Aug 2003 | B1 |
6605084 | Acker et al. | Aug 2003 | B2 |
6626900 | Sinofsky et al. | Sep 2003 | B1 |
6633773 | Reisfeld | Oct 2003 | B1 |
6635054 | Fjield et al. | Oct 2003 | B2 |
6648875 | Simpson et al. | Nov 2003 | B2 |
6650927 | Keidar | Nov 2003 | B1 |
6669655 | Acker et al. | Dec 2003 | B1 |
6676654 | Balle-Petersen et al. | Jan 2004 | B1 |
6676656 | Sinofsky | Jan 2004 | B2 |
6679873 | Rabiner et al. | Jan 2004 | B2 |
6702780 | Gilboa et al. | Mar 2004 | B1 |
6771996 | Bowe et al. | Aug 2004 | B2 |
6896673 | Hooven | May 2005 | B2 |
6907298 | Smits et al. | Jun 2005 | B2 |
6916306 | Jenkins et al. | Jul 2005 | B1 |
6932809 | Sinofsky | Aug 2005 | B2 |
6942657 | Sinofsky et al. | Sep 2005 | B2 |
6953457 | Farr et al. | Oct 2005 | B2 |
6997924 | Schwartz et al. | Feb 2006 | B2 |
7001383 | Keidar | Feb 2006 | B2 |
7113831 | Hooven | Sep 2006 | B2 |
7207984 | Farr et al. | Apr 2007 | B2 |
7217266 | Anderson et al. | May 2007 | B2 |
7250048 | Francischelli et al. | Jul 2007 | B2 |
7252664 | Nasab et al. | Aug 2007 | B2 |
7338485 | Brucker et al. | Mar 2008 | B2 |
7357796 | Farr et al. | Apr 2008 | B2 |
7367972 | Francischelli et al. | May 2008 | B2 |
7594925 | Danek et al. | Sep 2009 | B2 |
7662152 | Sharareh et al. | Feb 2010 | B2 |
7706860 | McGee | Apr 2010 | B2 |
7715604 | Sun et al. | May 2010 | B2 |
7935108 | Baxter et al. | May 2011 | B2 |
8025661 | Arnold et al. | Sep 2011 | B2 |
20010025174 | Daniel et al. | Sep 2001 | A1 |
20010030107 | Simpson | Oct 2001 | A1 |
20020019627 | Maguire et al. | Feb 2002 | A1 |
20020029062 | Satake | Mar 2002 | A1 |
20020065512 | Fjield et al. | May 2002 | A1 |
20020091383 | Hooven | Jul 2002 | A1 |
20020107511 | Collins et al. | Aug 2002 | A1 |
20020115995 | Lesh et al. | Aug 2002 | A1 |
20020120264 | Crowley et al. | Aug 2002 | A1 |
20020183729 | Farr et al. | Dec 2002 | A1 |
20020183739 | Long | Dec 2002 | A1 |
20030050632 | Fjield et al. | Mar 2003 | A1 |
20030065307 | Lesh | Apr 2003 | A1 |
20030069620 | Li | Apr 2003 | A1 |
20030111085 | Lesh | Jun 2003 | A1 |
20030120270 | Acker | Jun 2003 | A1 |
20030144657 | Bowe et al. | Jul 2003 | A1 |
20030158550 | Ganz et al. | Aug 2003 | A1 |
20030171746 | Fleischman | Sep 2003 | A1 |
20040006333 | Arnold et al. | Jan 2004 | A1 |
20040054360 | Schwartz et al. | Mar 2004 | A1 |
20040059397 | Sinofsky et al. | Mar 2004 | A1 |
20040122290 | Irion et al. | Jun 2004 | A1 |
20050038419 | Arnold et al. | Feb 2005 | A9 |
20050065471 | Kuntz | Mar 2005 | A1 |
20050065504 | Melsky et al. | Mar 2005 | A1 |
20050075629 | Chapelon et al. | Apr 2005 | A1 |
20050143793 | Korman et al. | Jun 2005 | A1 |
20050234436 | Baxter et al. | Oct 2005 | A1 |
20050234437 | Baxter et al. | Oct 2005 | A1 |
20050288654 | Nieman et al. | Dec 2005 | A1 |
20060122587 | Sharareh | Jun 2006 | A1 |
20060247683 | Danek et al. | Nov 2006 | A1 |
20060253113 | Arnold et al. | Nov 2006 | A1 |
20070073278 | Johnson et al. | Mar 2007 | A1 |
20070078451 | Arnold et al. | Apr 2007 | A1 |
20080015562 | Hong et al. | Jan 2008 | A1 |
20080015569 | Saadat et al. | Jan 2008 | A1 |
20080033410 | Rastegar et al. | Feb 2008 | A1 |
20080039746 | Hissong et al. | Feb 2008 | A1 |
20080108870 | Wiita et al. | May 2008 | A1 |
20080195088 | Farr et al. | Aug 2008 | A1 |
20090005768 | Sharareh et al. | Jan 2009 | A1 |
20090221996 | Lesh | Sep 2009 | A1 |
20090221997 | Arnold et al. | Sep 2009 | A1 |
20090275934 | Baxter et al. | Nov 2009 | A1 |
20090299354 | Melsky et al. | Dec 2009 | A1 |
20090326320 | Sinofsky et al. | Dec 2009 | A1 |
20100168738 | Schneider et al. | Jul 2010 | A1 |
20110082449 | Melsky et al. | Apr 2011 | A1 |
20110082450 | Melsky et al. | Apr 2011 | A1 |
20110082451 | Melsky | Apr 2011 | A1 |
20110082452 | Melsky et al. | Apr 2011 | A1 |
20110118714 | Deladi et al. | May 2011 | A1 |
20110245822 | Baxter et al. | Oct 2011 | A1 |
20110245828 | Baxter et al. | Oct 2011 | A1 |
Number | Date | Country |
---|---|---|
94117543 | Nov 1994 | DE |
0214712 | Mar 1987 | EP |
0292621 | Nov 1988 | EP |
0292695 | Nov 1988 | EP |
0299448 | Jan 1989 | EP |
0311458 | Apr 1989 | EP |
0437181 | Jul 1991 | EP |
0437183 | Jul 1991 | EP |
0439629 | Aug 1991 | EP |
0598984 | Jun 1994 | EP |
0792664 | Sep 1997 | EP |
1072231 | Jan 2001 | EP |
1331893 | Dec 2004 | EP |
2798371 | Mar 2001 | FR |
2003-210028 | Jul 2003 | JP |
2004-065076 | Mar 2004 | JP |
WO 9217243 | Oct 1992 | WO |
WO 9306888 | Apr 1993 | WO |
WO 9319680 | Oct 1993 | WO |
WO 9325155 | Dec 1993 | WO |
WO 9417434 | Aug 1994 | WO |
WO 9426184 | Nov 1994 | WO |
WO 9607451 | Mar 1996 | WO |
WO 9634646 | Nov 1996 | WO |
WO 9640342 | Dec 1996 | WO |
WO 9737714 | Oct 1997 | WO |
WO 0067656 | Nov 2000 | WO |
WO 0067832 | Nov 2000 | WO |
WO 0103599 | Jan 2001 | WO |
WO 0113812 | Mar 2001 | WO |
WO 0103599 | May 2001 | WO |
WO 0164123 | Sep 2001 | WO |
WO 02096479 | Dec 2002 | WO |
WO 03090835 | Nov 2003 | WO |
WO 2004-110258 | Dec 2004 | WO |
Entry |
---|
Reddy et al., View-Synchronized Robotic Image-Guided Therapy for Atrial Fibrillation Ablation Experimental Validation and Clinical Feasibility, Circulation. 2007;115:2705-2714. |
Eddins S, Steve on Image Processing, Mathworks Inc. Website, Aug. 20, 2008 http://blogs.mathworks.com/steve/2008/08/20/image-visualization-using-transparency/. |
Bredikis, J. et al. “Laser Destruction of the Atrioventricular Bundle Using the Cardiac Endoscope” Kardiologiia, 1988, 28(8): 94-96. |
Chevalier, P. et al. “Thoracoscopic Epicardial Radiofrequency Ablation for Vagal Atrial Fibrillation in Dogs” PACE, 1999, 22: 880-886. |
Froelich, J. et al. “Evaluation of a Prototype Steerable Angioscopic Laser Catheter in a Canine Model: A Feasibility Study” Cardiovasc Intervent Radiol, 1993 16: 235-238. |
Fujimura, O. et al. “Direct in Vivo Visualization of Right Cardiac Anatomy by Fiberoptic Endoscopy” Angiology; 1995, 46 (3): 201-208. |
Fujimura, O. et al. “Direct In Vivo Visualization of Right Cardiac Anatomy by Fiberoptic Endoscopy: Observation of Radiofrequency-Induced Acute Lesions Around the Ostium of the Coronary Sinus” European Heart J., 1994, 15: 534-540. |
Gamble, W. and Innis, R. “Experimental Intracardiac Visualization” NEJM, 1967, 276(25): 1397-1403. |
Hirao, K. et al. “Transcatheter Neodymium—Yttrium—Aluminum—Garnet Laser Coagulation of Canine Ventricle Using a Balloon-Tipped Cardioscope” Jpn Circ J., 1997, 61: 695-703. |
Keane, D. et al. “Pulmonary Vein Isolation for Atrial Fibrillation” Rev Cardiovasc Med., 2002, 3(4): 167-175. |
Kuo, C. et al. “In Vivo Angioscopic Visualization of Right Heart Structure in Dogs by Means of a Balloon-Tipped Fiberoptic Endoscope: Potential Role in Percutaneous Ablative Procedures.” American Heart J., 1994, 127: 187-197. |
Nakagawa, H. et al. “Cardioscopic Catheter Ablation with Non-contact, Pulsed Nd:YAG Laser Using Saline Inflated Balloon Catheter,” Presentation JACC 1998; 31: 118A-119A. |
Obelienius, V. et al. “Transvenous Ablation of the Atrioventricular Conduction System by Laser Irradiation Under Endoscopic Control” Lasers in Surgery Medicine, 1985, 5: 469-474. |
Roggan, A., et al. “Optical Properties of Circulating Human Blood in the Wavelength Range 400-2400 nm” J Biomedical Optics, 1999, 4(1): 36-46. |
Saliba, W. et al. “Circumferential Ultrasound Ablation for Pulmonary Vein Isolation: Analysis of Acute and Chronic Failures” J Cardiovascular Electrophysiology, 2002, 13(10): 957-961. |
Shure, D. et al. “Identification of Pulmonary Emboli in the Dog: Comparison of Angioscopy and Perfusion Scanning” Circulation, 1981, 64(3): 618-621. |
Shure, D., et al. “Fiberoptic Angioscopy: Role in the Diagnosis of Chronic Pulmonary Arterial Obstruction” Ann Int Med., 1985, 103: 844-850. |
Tanabe, T. et al. “Cardiovascular Fiberoptic Endoscopy: Development and Clinical Application” Surgery, 1980, 87(4): 375-379. |
Tanaka, K. et al., “Endoscopy-Assisted Radiofrequency Ablation Around the Coronary Sinus Ostium in Dogs: Its Effects on Atrioventricular Nodal Properties and Ventricular Response During Atrial Fibrillation,” Journal of Cardiovascular Electrophysiology, vol. 7, No. 11, Nov. 1996, pp. 1063-1073. |
Uchida, Y. et al. “Fiberoptic Angioscopy of Cardiac Chambers, Valves, and Great Vessels Using a Guiding Balloon Catheter in Dogs.” American Heart J., 1998, 115(6): 1297-1302. |
Uchida, Y. et al. “Percutaneous Pulmonary Angioscopy Using a Guiding Balloon Catheter” Clin. Cardiol., 1988, 11: 143-148. |
Vanermen, H. et al. “Minimally Invasive Video-Assisted Mitral Valve Surgery: From Port-Access Towards a Totally Endoscopic Procedure” J Card Surg., 2000, 15: 51-60. |
Yamamoto, N. et al. “Nonfluoroscopic Guidance for Catheter Placement into the Coronary Sinus under Direct Vision Using a Balloon-Tipped Cardioscope” PACE, 1998; 21: 1724-1729. |
Number | Date | Country | |
---|---|---|---|
20110082451 A1 | Apr 2011 | US |
Number | Date | Country | |
---|---|---|---|
61249182 | Oct 2009 | US |